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KEY MESSAGE
Akt/PKB inhibitor GSK690693, CK2 inhibitor ARC-775, MAPK pathway inhibitor sorafenib, proteasome 
inhibitor bortezomib, and microtubule-depolymerizing toxin MMAE showed higher cytotoxicity in eutopic 
cells. In contrast, 10 µmol/l of the anthracycline toxin doxorubicin caused cellular death in ectopic cells more 
effectively than in eutopic cells, underlining the potential of doxorubicin in endometriosis research.
ABSTRACT
Research question: Endometriosis is a common gynaecological disease defined by the presence of endometrium-like tissue outside 
the uterus. This complex disease, often accompanied by severe pain and infertility, causes a significant medical and socioeconomic 
burden; hence, novel strategies are being sought for the treatment of endometriosis. Here, we set out to explore the cytotoxic effects 
of a panel of compounds to find toxins with different efficiency in eutopic versus ectopic cells, thus highlighting alterations in the 
corresponding molecular pathways.
Design: The effect on cellular viability of 14 compounds was established in a cohort of paired eutopic and ectopic endometrial stromal 
cell samples from 11 patients. The biological targets covered by the panel included pro-survival enzymes, cytoskeleton proteins, the 
proteasome and the cell repair machinery.
Results: Protein kinase inhibitors GSK690693, ARC-775 and sorafenib, proteasome inhibitor bortezomib, and microtubule-
depolymerizing toxin monomethyl auristatin E were more effective in eutopic cells. In contrast, 10 µmol/l of the anthracycline 
toxin doxorubicin caused cellular death in ectopic cells more effectively than in eutopic cells. The large-scale sequencing of mRNA 
isolated from doxorubicin-treated and control cells indicated different survival strategies in eutopic versus ectopic endometrium.
Conclusions: Overall, the results confirm evidence of large-scale metabolic reprogramming in endometriotic cells, which underlies 
the observed differences in sensitivity towards toxins. The enhanced efficiency of doxorubicin interfering with redox equilibria and/
or DNA repair mechanisms pinpoints key players that can be potentially used to selectively target ectopic lesions in endometriosis.
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INTRODUCTION
E ndometriosis is an inflammatory gynaecological disease that manifests itself as a growth of endometrial stromal cells (ESC) 
and epithelial cells in extrauterine sites. 
Endometriosis is estimated to affect 
2–10% of women in their reproductive 
years, and as there are still no effective 
non-surgical treatments, it has a 
considerable impact on the quality of 
life of women affected (Nnoaham 
et al., 2011). Endometriosis-associated 
symptoms such as severe pelvic pain, 
infertility and impaired psychological and 
social functioning cause a socioeconomic 
burden from loss of productivity; 
furthermore, the risk of developing 
ovarian cancer is moderately increased 
in women suffering from endometriosis, 
being about 1.9% compared with 1.4% in 
the general population (Vercellini et al., 
2018). Therefore, the new possibilities in 
the treatment of endometriosis are being 
actively explored.
To find potent strategies for treating 
endometriosis, the mechanisms behind 
disease initiation need to be understood. 
The formation of endometriotic lesions 
presupposes an ability of endometrial cells 
to attach to peritoneal surfaces, establish 
neo-angiogenesis and resist apoptosis 
(Nasu et al., 2009). Characteristics 
such as a high degree of inflammation, 
an excess of iron and an increase in 
reactive oxygen species (ROS) have also 
been described in endometriotic lesions 
(Defrere et al., 2008; Lousse et al., 2012; 
Scutiero et al., 2017). Furthermore, a 
comprehensive proteomic study by the 
current group has shown that extensive 
metabolic reprogramming (associated with 
down-regulation of oxidative respiration) 
and an up-regulation of proteins 
involved in adhesiveness and motility 
occur in endometriotic stromal cells 
(Kasvandik et al., 2016), emphasizing the 
similarities between endometriotic and 
cancer cells. Therefore toxins affecting 
various molecular pathways in cancer 
chemotherapy could find an alternate 
application in research into – and 
potentially therapy of – endometriosis. 
Some such compounds have been briefly 
explored in the context of endometriosis 
(Celik et al., 2008) yet we are not aware of 
studies with a focused panel of toxins that 
would systematically compare the effect of 
compounds in eutopic and ectopic cells 
taken from women with endometriosis.
This paper reports on quantification of 
the cytotoxic effect of 14 compounds 
(TABLE 1) in a cohort of paired eutopic 
and ectopic ESC (euESC and ecESC) 
samples from 11 patients. The biological 
targets covered by this panel included 
pro-survival enzymes, cytoskeleton 
proteins, the proteasome and the cell 
repair machinery. The rationale behind 
the choice of compounds took into 
consideration the high affinity and well-
defined selectivity profile of inhibitors in 
biochemical studies and their applicability 
in cellular assays. The goal was to find 
compounds demonstrating different 
efficiency in eutopic versus ectopic cells 
from peritoneal lesions, thus highlighting 
alterations in the corresponding 
molecular pathways, and to pinpoint 
compounds that preferentially affect 
ectopic cells, thus paving the way for 
future possible therapeutic strategies.
MATERIALS AND METHODS
Chemicals and equipment
Protein kinase inhibitors were obtained 
from the following sources: SGI-
1776 – Axon Medchem (Groningen, 
Netherlands); H-89 – Biaffin (Kassel, 
Germany); sorafenib, Y-27632, HA-1077 
– Cayman Chemical (Ann Arbor, MI, 
USA); staurosporine – Cell Guidance 
Systems (Cambridge, UK); VX-689, 
CYC116 – Selleckchem (Houston, 
TX, USA); bortezomib, monomethyl 
auristatin E (MMAE), doxorubicin – 
TBD-Biodiscovery (Tartu, Estonia); 
and GSK690693 – Tocris (Bristol, 
UK). ARC-775 and ARC-1859 were 
kindly gifted by Dr Asko Uri (University 
of Tartu, Tartu, Estonia). The stock 
solutions of compounds (5–10 mmol/l in 
dimethylsulphoxide [DMSO]) were stored 
at –20°C. SYTOX Blue Nucleic Acid 
TABLE 1 COMPOUNDS USED IN THE STUDY
Name Concentrations 
used (µmol/l)
Major biological target References
GSK690693 0.4, 2, 10 Akt/PKB 1, 2, 3 (Levy et al., 2009; Rhodes et al., 2008)
VX-689 (MK5108) 0.2, 1, 5 Aurora A (Chinn et al., 2014; Shimomura et al., 2010)
CYC116 0.4, 2, 10 Aurora A, B (Jayanthan et al., 2014; Wang et al., 2010)
ARC-775 0.4, 2, 10 CK2 (Rahnel et al., 2017)
ARC-1859 0.4, 2, 10 CK2 (Viht et al., 2015)
SGI-1776 0.4, 2, 10 PIM 1, 3 (Chen et al., 2011, 2009)
H-89 0.4, 2, 10 PKA, PKG1 (Dabizzi et al., 2003; Yoshino et al., 2003)
Y-27632 0.4, 2, 10 ROCK 1, 2 (Grewal et al., 2010; Yotova et al., 2011; Yuge et al., 2007)
HA-1077 (fasudil) 0.4, 2, 10 ROCK 2 (Tsuno et al., 2011)
Sorafenib (BAY 43-9006) 0.4, 2, 10 RAF1, BRAF, KDR (VEGFR2), 
FLT4 (VEGFR3)
(Llobet et al., 2010; Moggio et al., 2012)
Staurosporine 0.2, 1, 5 PKCα, γ, η (Izawa et al., 2006; Watanabe et al., 2009)
Bortezomib (PS-341, Velcade) 0.4, 2, 10 20S proteasome (Kao et al., 2014)
Doxorubicin (adriamycin) 0.4, 2, 10 DNA, topoisomerase-II (Byron et al., 2012; Chitcholtan et al., 2012)
Monomethyl auristatin E (MMAE) 0.04, 0.2, 1 Tubulin (Abdollahpour-Alitappeh et al., 2017; Chen et al., 2017)
Abbreviations: Akt/PKB, protein kinase B; BRAF, V-Raf murine sarcoma viral oncogene homolog B; CK2, casein kinase 2; PIM, proto-oncogene Ser/Thr-protein kinase; PKA, 
protein kinase A; PKC, protein kinase C; RAF1, V-Raf-1 murine leukemia viral oncogene homolog 1; ROCK, Rho-dependent protein kinase; VEGFR, vascular endothelial 
growth factor receptor.
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Stain and NP40 lysis buffer were from 
Thermo Fischer Scientific (Rockford, 
IL, USA); cell culture grade DMSO was 
from AppliChem (Darmstadt, Germany); 
resazurin, bovine serum albumin (BSA) 
and phosphate-buffered saline (PBS) 
(supplemented with Ca2+ and Mg2+; used 
for the biochemical assays and western 
blotting) were from Sigma-Aldrich (St 
Louis, MO, USA). Other solutions, 
reagents and materials for sodium 
dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and western 
blotting were from Thermo Fischer 
Scientific (Carlsbad, CA, USA).
For the necrosis/late apoptosis and 
viability assays, the initial number of cells 
was counted using a TC10 cell counter 
(Bio-Rad, Hercules, CA, USA), and the 
cells were seeded onto transparent 96-
well, clear, flat-bottom cell culture plates 
(BioLite 130188; Thermo Fischer Scientific, 
Rochester, NY, USA). Fluorescence 
intensity and absorbance measurements 
were made using Synergy NEO, Cytation 
5 (both from Biotek, Winooski, VT, 
USA) and PHERAstar (BMG Labtech, 
Ortenberg, Germany) multimode readers.
Patient characteristics and sample 
collection
The study was approved by the 
Research Ethics Committee of the 
University of Tartu (approval 276/M-13) 
on 18 December 2017 and informed 
written consent was obtained from the 
participants. Endometrial tissue samples 
and peritoneal endometriotic lesions were 
collected from 11 women endometriosis 
(TABLE 2) undergoing laparoscopy at the 
Tartu University Hospital Women's Clinic. 
Tissue samples were immediately placed 
into the cryopreservation medium and 
processed as previously described (Rekker 
et al., 2017). At least one endometriotic 
lesion sample from each patient was 
placed into formalin and the diagnosis 
was confirmed by histopathological 
examination of the specimens. Disease 
severity was determined according to 
the American Society for Reproductive 
Medicine revised classification system 
(American Society for Reproductive 
Medicine, 1997). Only women who had 
not received any hormonal medications 
for at least 3 months before surgery were 
enrolled in this study.
Isolation and culturing of cells
Endometriotic and endometrial tissues 
were treated according to the previously 
published protocol (Kasvandik et al., 
2016). Briefly, the tissue was washed twice 
in 7 ml of fresh medium (a 1:1 mixture 
of Dulbecco's modified Eagle's medium 
[DMEM] and Ham's F-12; Sigma-Aldrich, 
Steinheim, Germany) to remove any 
debris or excess blood cells. The biopsies 
were dissociated in 5 ml of DMEM 
(without phenol red) containing 0.5% 
collagenase (Sigma-Aldrich) in a shaking 
incubator rotating at 110 rpm at 37°C 
until the biopsies had been digested (but 
not for longer than 1 h). The dispersed 
cells were filtered through a 50 µm 
nylon mesh to remove undigested tissue 
pieces. Next, the cells were resuspended 
in 10 ml of culture medium in a 15 ml 
tube; the sealed tubes were placed 
in an upright position for 10 min to 
sediment the epithelial glands. The top 
8 ml of medium containing stromal cells 
was then collected and the tube was 
refilled to 10 ml with fresh medium; the 
sedimentation process was repeated 
three times and the collected fractions 
were pooled. The final purification of 
stromal cells was achieved by selective 
adherence of stromal cells to culture 
dishes for 20–30 min at 37°C in 5% CO2 
in an incubator. Non-adhering epithelial 
cells were removed by washing the cell 
layer twice with 5 ml of culture medium.
The isolated ESC were further cultured 
for 5–6 passages in DMEM/Ham's 
F-12 medium supplemented with 10% 
fetal bovine serum (FBS; Capricorn, 
Ebsdorfergrund, Germany) and a 
mixture of penicillin, streptomycin 
and amphotericin B (Capricorn, 
Ebsdorfergrund, Germany) at 37°C in 
5% CO2 in an incubator.
Necrosis/late apoptosis assay
euESC and ecESC (passage number 
5–6) were seeded onto 96-well plates at 
a density of 4000–6000 cells per well in 
DMEM/Ham's F-12 medium supplemented 
with FBS; euESC and ecESC from the 
same patient were thawed on the same 
day, and two plates were prepared for 
both eutopic and ectopic stromal cells. 
After incubating the cells for 24 h at 37°C 
in 5% CO2 in a humidified incubator, 
the medium was exchanged and dilution 
series of compounds in PBS were added 
(see TABLE 1); the final volume per well was 
110 µl, and the concentration of DMSO 
in the treated wells was ≤0.1% by volume. 
For each plate, each concentration 
of each compound to be tested was 
represented in duplicate; the controls 
(10% DMSO and 0.1% DMSO) were 
represented in sextuplicate. The cells 
were incubated with the compounds for 
22 h at 37°C in 5% CO2 in a humidified 
incubator; next, the medium was removed 
TABLE 2 CHARACTERISTICS OF THE STUDY PARTICIPANTS
Patient ID Age (years) BMI (kg/m2) Endometriosis stage Location of lesion Study
E048 29 19.8 III Lig. sacrouterina SUP N, V
E044 32 23.7 III Excavatio vesicouterina SUP N, V
E041 39 25.6 I Fossa ovarica SUP N, V
E205 36 22.2 I Lig. latum SUP N, V
E242 30 20.1 I Lig. sacrouterina SUP N, V
E262 40 29.8 II–III Lig. latum SUP N, V, V2, WB, seq
E267 25 22.1 I Pouch of Douglas SUP N, V, V2, WB
E270 33 21.6 III Lig sacrouterina SUP N, V
E278 32 20.8 I Excavatio vesicouterina SUP N, V, V2, WB, seq
E279 22 21.4 I Excavatio vesicouterina SUP N, V, V2, WB, seq
E310 24 23.5 I Lig. sacrouterina SUP N, V
Lig., ligamentum; N, necrosis/late apoptosis assay; seq, mRNA sequencing; SUP, superficial; V, viability assay with large cohort; V2, viability assay with small cohort; WB, western blot.
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and 1 µmol/l Sytox Blue solution in PBS 
(containing Ca2+ and Mg2+) was added. 
The plates were placed into a multimode 
reader and incubated for 10 min at 
37°C, and the fluorescence intensity was 
measured (excitation 430 nm, emission 
480 nm, monochromator, top optics, gain 
90; area scan mode 5  ×  5, read height 
2.5 mm, with lid).
Viability assay
The viability assay was performed directly 
after the necrosis/late apoptosis assay 
using the same plates. The solution of 
Sytox Blue was replaced by 50 µmol/l 
resazurin solution in PBS (containing 
Ca2+ and Mg2+). The plates were 
placed into the multimode reader, 
and measurement of absorbance was 
performed (570 nm and 600 nm, 
monochromator; kinetic mode with 
a reading taken every 15 min for 2 h, 
read height 8.5 mm, with lid). Next, 
resazurin solution was replaced by fresh 
sterile DMEM/Ham's F-12 medium 
supplemented with FBS, and the cells 
were incubated for 24 h at 37°C in 5% 
CO2 in a humidified incubator. Finally, 
the viability assay was performed again 
(without the preceding necrosis/late 
apoptosis assay). In a pilot experiment, it 
was confirmed that the first application 
of resazurin for 2 h in PBS did not cause 
severe cytotoxicity (data not shown).
Western blotting
For the western blot assay, one 6-well 
plate was prepared for euESC and one 
plate for ecESC (passage number 5–6). 
When the confluency of cells was 50% 
or higher, dilutions of doxorubicin in PBS 
or DMSO in PBS (control) were added. 
The final volume per well was 2 ml; the 
final concentration of doxorubicin was 
10 µmol/l, and the final concentration of 
DMSO was 0.1%. On each plate, both 
doxorubicin and control incubations were 
represented in duplicate. The cells were 
incubated for 48 h at 37°C in 5% CO2 in 
a humidified incubator.
After collection and lysis of the cells on ice, 
the samples for SDS-PAGE were prepared 
by adding NuPAGE sample loading buffer 
(ThermoFisher, Carlsbad, CA, USA) to 
supernatants and heating at 70°C for 
15 min. SDS-PAGE was performed on 10% 
Bis-Tris gels or 4–12% Bis-Tris gradient gel 
(ThermoFisher, Carlsbad, CA, USA) in 
MES buffer (ThermoFisher, Carlsbad, CA, 
USA); samples of treated and untreated 
euESC and ecESC from the same patients 
were applied on different lanes of the 
same gel. Semi-dry transfer followed 
at 15 V for 60 min using methanol-
activated polyvinylidene difluoride (PVDF) 
membrane and NuPAGE transfer buffer. 
The membrane was then stained with 
primary antibody (1,000 × dilution of rabbit 
anti-procaspase-3; catalogue number 
9662 Cell Signaling, RRID: AB_331439) 
and secondary antibody (5,000 × dilution 
of goat anti-rabbit conjugated to alkaline 
phosphatase; T2191 Thermo Fischer 
Scientific, RRID: AB_11180336) according to 
the manufacturers’ instructions. The same 
procedure was used for the subsequent 
staining of the same membrane with 
mouse antibeta-actin (4,000 × dilution; 
A1978 Sigma-Aldrich, RRID: AB_476692) 
and goat anti-mouse conjugated to 
alkaline phosphatase (5,000 × dilution; 
T2192 Thermo Fischer Scientific, RRID: 
AB_11180852).
mRNA isolation and large-scale 
sequencing
euESC (n = 3) and ecESC (n = 3) were 
isolated and grown as described in the 
sections on the isolation and culturing of 
cells and western blotting, respectively; 
the cells were isolated from the paired 
eutopic and ectopic samples that were 
included in western blot studies. After 
24 h incubating the cells with a final 
concentration of 2 µmol/l doxorubicin 
or 0.1% DMSO (as a negative control) 
in growth medium, the medium was 
removed, the cells were rinsed with PBS 
and RNA was extracted using RNeasy 
Mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer's protocol. 
DNase I treatment was performed 
using the DNA-free DNA removal kit 
(Invitrogen, Carlsbad, CA, USA). A 2200 
TapeStation system in conjunction with 
RNA ScreenTape (Agilent Technologies, 
Palo Alto, CA, USA) was used to 
determine the quality and quantity of 
purified RNA. For sequencing library 
construction, RNA from two technical 
replicates was pooled together. cDNA 
was synthesized as previously described 
(Teder et al., 2018), converted to the 
next-generation sequencing library using 
a Nextera XT Library Prep kit (Illumina, 
San Diego, CA, USA) and sequenced with 
NextSeq 500 high output 75 cycles kit 
(Illumina, San Diego, CA, USA).
Quantitative real-time PCR
The expression levels of selected genes 
(HSPA2, PTGS2 and PTN) were validated 
by quantitative real-time PCR (qRT-
PCR) using RNA from two technical 
replicates. cDNA was synthesized 
using a RevertAid First Strand cDNA 
Synthesis Kit (Thermo Fisher Scientific, 
Waltham, MA, USA), and real-time PCR 
was performed using 1 × HOT FIREPol 
EvaGreen qPCR Mix Plus (ROX) (Solis 
BioDyne, Tartu, Estonia). The primer 
sequences used were as follows: HSPA2 
(F: CTCCACTCGTATCCCCAAGA, R: 
GTCACGTCGAGTAGCAGCAG), PTGS2 
(F: CCACTTCAAGGGATTTTGGA, 
R: GAGAAGGCTTCCCAGCTTTT) 
and PTN (F: CAATGCCGAATGCCA 
GAAGACTGT, R: TCCACAGGTGACA 
TCTTTTAATCC). ACTB (F: TCAAG 
ATCATTGCTCCTCC and R: ACATCTG 
CTGGAAGGTGGA) was used as a 
reference gene.
Statistical analysis
Data are available on request from the 
authors.
For the necrosis/late apoptosis assay, 
the mean Sytox Blue fluorescence 
intensity per well was calculated; the data 
corresponding to the same concentration 
of the same compound were pooled 
and normalized for each plate. For 
normalization, the signal obtained for 
incubation with 5 µmol/l staurosporine 
was considered to be 100% necrosis, and 
the signal obtained for incubation with 
0.1% DMSO as 0% necrosis.
For the viability assay, the ratio of the 
absorbances at 570 nm and 600 nm 
was calculated for each well. The data 
obtained from one plate for the control 
incubations with 0.1% DMSO or 10% 
DMSO were pooled and plotted against 
time, and the linear range of the assay 
was established. The data corresponding 
to the same concentration of the same 
compound were pooled and normalized 
for each plate. For normalization, data 
obtained for incubation with 10% DMSO 
were considered as 0% viability, and data 
obtained for incubation with 0.1% DMSO 
as 100% viability.
For western blot data analysis, the 
membrane was dried and scanned in. 
The area of bands detected with anti-
procaspase-3 and anti-beta–actin was 
assessed using ImageJ 1.51j8 software 
(Bethesda, MD, USA), and the ratio of the 
two values was calculated for each lane; 
the data were pooled for the lanes where 
the identically treated samples of the same 
cells had been applied. Next, data for lanes 
with samples from euESC and ecESC were 
normalized separately. For normalization, 
ratio obtained for incubation with 0.1% 
560 RBMO  VOLUME 39  ISSUE 4  2019
DMSO was considered as 100% to obtain 
results for one patient; the bottom plateau 
was fixed at 0%.
In the case of qRT-PCR, the average 
values of technical replicates were 
used. The fold change  was calculated 
according to the 2−ΔΔCT method (Livak 
and Schmittgen, 2001).
For the final comparison, the results of 
all the patients were pooled. For the 
necrosis/late apoptosis and viability 
assays, the statistical significance for 
the difference between the inhibitor/
toxin-treated cells and the cells treated 
with 0.1% DMSO was established by 
ordinary one-way analysis of variance 
using Dunnett's correction for multiple 
comparisons (P ≤ 0.05 was considered 
significant). For the necrosis/late 
apoptosis and viability assays as well 
as the western blotting, the statistical 
significance of the difference between 
euESC and ecESC was established by an 
unpaired t-test with Welch's correction 
(P ≤ 0.05 was considered significant). 
For the qRT-PCR data, the statistical 
significance of the difference between 
control and doxorubicin treatment 
was established using a paired t-test 
(P ≤ 0.05 was considered significant), 
and the statistical significance of the 
difference between euESC and ecESC 
was established using an unpaired 
t-test (again, P ≤ 0.05 was considered 
significant). The aforementioned 
statistical analysis was carried out using 
GraphPad Prism 6 (San Diego, CA, USA).
The large-scale mRNA sequencing data 
were acquired using Illumina BaseSpace 
(San Diego, CA, USA). The reads were 
quantified with Salmon 0.9.1 (New York, 
USA / Pittsburgh, PA, USA) in quasi-
mapping mode using indexed Ensemble 
v95 annotation. The quality control 
of raw sequencing data and statistics 
on aligned counts was performed 
with FastQC 0.11.5 (Babraham, UK) 
and MultiQC 1.7 (Stockholm/Uppsala, 
Sweden). Based on the quality control, 
further data transformation was 
performed by trimming the adapter 
size with Trimmomatic 0.38 (Jülich, 
Germany). Quantified transcript read 
counts were summarized to genes using 
Bioconductor packages tximport 1.10.1 
(Boston, MA, USA / Zurich, Switzerland) 
and BioMart 2.38.0 (Berkeley, CA, 
USA / Cambridge, UK). Overall, 175,775 
transcripts were identified from all the 
samples, out of which 28,796 genes with 
non-zero total counts were summarized. 
Differential RNA sequencing analysis and 
ranking was performed with DESeq2 
1.22.2 (Heidelberg, Germany). edgeR 
3.24.3 (Parkville, Australia) was used in 
parallel for comparison.
The shortlist of genes with significantly 
different (P-value adjusted for false 
discovery rate, Padj < 0.05) expression 
in pairwise compared cell types and 
treatment conditions (control euESC 
versus control ecESC; control euESC 
versus toxin-treated euESC; control 
ecESC versus toxin-treated ecESC; 
and toxin-treated euESC versus toxin-
treated ecESC) was generated as 
follows. The data for expression of each 
gene obtained in the same cell type 
and condition were averaged for three 
patients, and the binary logarithm of 
the fold change of averages (log2FC) 
was determined. For each pairwise 
comparison, the latter values were 
ranked and cut-off values of log2FC 
less than or equal to 4 or ≥+4 were 
applied. The genes showing high 
variance in expression (for the same cell 
type and condition between different 
patients) and the genes for which the 
number of counts was below 10 in all 
conditions were eliminated. Finally, after 
the individual check of the remaining 
candidates using the GeneCards human 
gene database (Weizmann Institute of 
Science, 2019) and g:Profiler source 
(Reimand et al., 2016), the pseudogenes 
and the genes encoding poorly 
characterized proteins were excluded 
from the list.
RESULTS
Viability assay
To establish the effect of the compounds 
(shown in TABLE 1) on the viability of 
euESC and ecESC, an assay was used 
that measures the change in absorbance 
spectrum of the cell membrane-
penetrating dye resazurin upon its 
biochemical reduction in metabolically 
active cells. TABLE 3 summarizes the results 
of the viability assay in which a statistically 
significant reduction of viability (P ≤ 0.01) 
was observed after 22 h incubation of 
cells with the studied compounds and 
after an additional 24 h incubation in 
growth medium; the full versions of the 
data are presented in the Supplemental 
Tables S1 and S2.
As expectedly, the lowest viability after 
22 h of treatment was observed for 
both euESC and ecESC treated with 
the well-known apoptosis inducer 
staurosporine. SGI-1776, a pan-inhibitor 
of proto-oncogene Ser/Thr-protein 
kinase Pim family, caused a significant fall 
in viability at 10 µmol/l concentration in 
both euESC and ecESC (P ≤ 0.001); it 
was also the only compound in the panel 
demonstrating a large patient-dependent 
effect: out of 11 patients’ samples, low 
viability of the cells was evident in the 
samples from three patients, whereas 
those from four patients were practically 
insensitive (Supplemental Figure S1A). 
Other inhibitors of protein kinases did 
not cause an extended amount of cell 
death in either euESC or ecESC (the 
viability of cells remained at 75% or more 
relative to the 0.1% DMSO control). 
Interestingly, after 22 h incubation of 
cells with the Rho-dependent protein 
kinase inhibitor HA-1077, an apparent 
increase in viability was observed in 
both in euESC and ecESC (i.e. cells 
treated with 10 µmol/l inhibitor had 
higher values for resazurin reduction 
than cells treated with 0.1% DMSO). A 
similar phenomenon was evident in both 
in euESC and ecESC on treatment with 
different concentrations of VX-689, and 
in ecESC on treatment with 10 µmol/l or 
2 µmol/l ARC-1859 (see Supplemental 
Table S1). Chemotherapeutic drugs 
bortezomib and MMAE were more 
efficient in eutopic cells, although a 
significant fall in viability was observed 
in both euESC and ecESC (P ≤ 0.001). 
Conversely, treatment with 10 µmol/l 
and 2 µmol/l doxorubicin was more 
efficient in ecESC than euESC, showing 
a similar effect across all patients (see 
Supplemental Figure S1A).
The measurement of cell viability after 
the subsequent 24 h incubation in 
growth medium demonstrated that the 
viability of most toxin-treated euESC 
and ecESC had decreased further, and 
differences in results between euESC 
and ecESC had become smaller (TABLE 3). 
In addition, a significant decrease of 
viability was now observed for cells 
treated with the mitogen-activated 
protein kinase (MAPK) pathway inhibitor 
sorafenib (P ≤ 0.05), protein kinase 
A (PKA) inhibitor H-89 (P ≤ 0.01) and 
Aurora A inhibitor VX-689 (P ≤ 0.01; a 
fuller version of 22 h + 24 h results from 
TABLE 3 is presented as Supplemental 
Table S2). Although sorafenib and H-89 
were slightly more active in euESC, the 
effect of VX-689 was more pronounced 
in ectopic cells. Notably, after prolonged 
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incubation, 10 µmol/l doxorubicin still 
affected ecESC more than euESC. The 
increased sensitivity of ecESC towards 
high concentrations of doxorubicin 
was confirmed in a repeated assay with 
samples representing four patients 
from the same cohort (Supplemental 
Figure S2).
All in all, based on the results of the 
viability assay, characteristic differences 
in the viability fingerprint between euESC 
and ecESC could be formulated (FIGURE 1).
TABLE 3 COMPOUNDS INDUCING A SIGNIFICANT DECREASE IN VIABILITY OF EUESC AND/OR ECESC AFTER 22 H AND 
PROLONGED TREATMENT
Compound Concentration Incubation 
timea
% of viability 
in euESCb
% of viability 
in ecESCb
Difference euESC 
versus ecESCc
GSK690693 10 µmol/l 22 h 86 ± 2 *** 94 ± 2 ns * (euESC)
22 h + 24 h 78 ± 2 *** 87 ± 2 *** ** (euESC)
2 µmol/l 22 h 89 ± 2 ** 94 ± 2 ns ns
22 h + 24 h 85 ± 2 *** 89 ± 2 *** ns
CYC116 10 µmol/l 22 h 89 ± 2 *** 103 ± 2 ns *** (euESC)
22 h + 24 h 87 ± 2 *** 93 ± 2 ** * (euESC)
ARC-775 10 µmol/l 22 h 77 ± 2 *** 90 ± 2 *** *** (euESC)
22 h + 24 h 67 ± 2 *** 70 ± 2 ** ns
2 µmol/l 22 h 90 ± 2 *** 102 ± 2 ns *** (euESC)
22 h + 24 h 92 ± 2 *** 91 ± 2 *** ns
SGI-1776 10 µmol/l 22 h 56 ± 5 *** 62 ± 5 *** ns
22 h + 24 h 48 ± 4 *** 57 ± 4 *** ns
Staurosporine 5 µmol/l 22 h 15 ± 1 *** 6 ± 1 *** *** (ecESC)
22 h + 24 h 4 ± 1 *** 3 ± 1 *** ns
1 µmol/l 22 h 27 ± 3 *** 24 ± 1 *** ns
22 h + 24 h 16 ± 2 *** 15 ± 2 *** ns
0.2 µmol/l 22 h 41 ± 3 *** 50 ± 2 *** ** (euESC)
22 h + 24 h 30 ± 2 *** 41 ± 2 *** *** (euESC)
Bortezomib 10 µmol/l 22 h 26 ± 2 *** 40 ± 2 *** *** (euESC)
22 h + 24 h 5 ± 1 *** 16 ± 2 *** *** (euESC)
2 µmol/l 22 h 33 ± 1 *** 42 ± 2 *** *** (euESC)
22 h + 24 h 12 ± 1 *** 23 ± 2 *** *** (euESC)
0.4 µmol/l 22 h 39 ± 2 *** 53 ± 2 *** *** (euESC)
22 h + 24 h 18 ± 1 *** 39 ± 2 *** *** (euESC)
Doxorubicin 10 µmol/l 22 h 78 ± 2 *** 59 ± 2 *** *** (ecESC)
22 h + 24 h 38 ± 2 *** 22 ± 2 *** *** (ecESC)
2 µmol/l 22 h 78 ± 2 *** 64 ± 2 *** *** (ecESC)
22 h + 24 h 39 ± 2 *** 37 ± 2 *** ns
0.4 µmol/l 22 h 85 ± 2 *** 83 ± 2 *** ns
22 h + 24 h 67 ± 3 *** 68 ± 2 *** ns
Monomethyl auristatin E 
(MMAE)
1 µmol/l 22 h 60 ± 2 *** 65 ± 1 *** * (euESC)
22 h + 24 h 47 ± 2 *** 53 ± 2 *** * (euESC)
0.2 µmol/l 22 h 60 ± 2 *** 66 ± 2 *** * (euESC)
22 h + 24 h 49 ± 2 *** 57 ± 2 *** ** (euESC)
0.04 µmol/l 22 h 61 ± 2 *** 64 ± 1 *** ns
22 h + 24 h 49 ± 2 *** 59 ± 2 *** *** (euESC)
Data are mean normalized viability ± SEM.
a Incubation with inhibitors was performed for 22 h, followed by the addition of growth medium for 24 h.
b n = 11 for the 22 h measurement and n = 10 for the 22 h + 24 h measurement. Data obtained for incubation with 10% dimethylsulphoxide (DMSO) were considered to 
show 0% viability, and data obtained for incubation with 0.1% DMSO were considered to show 100% viability. Significance of effect difference relative to the negative control 
(treated with 0.1% DMSO): ***P ≤ 0.001; **P ≤ 0.01; *P ≤ 0.05; ns, P > 0.05.
c Significance of effect difference between euESC and ecESC; the cell type with the lowest viability is shown in brackets. ***P ≤ 0.001; **P ≤ 0.01; *P ≤ 0.05; ns, P > 0.05.
ecESC, ectopic endometrial stromal cell; euESC, eutopic endometrial stromal cell.
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Necrosis/late apoptosis assay
To confirm the trends observed in 
viability studies, we applied an additional 
assay by using cell membrane-
impermeable Sytox Blue dye after 22 h 
incubation of euESC and ecESC with 
the different compounds. The increase 
in fluorescence of Sytox Blue resulting 
from intercalation of dye into the DNA is 
only possible in cells with compromised 
membrane structure, indicating an 
elevated extent of necrosis/late apoptosis.
The results of the assay are presented in 
the Supplemental Table S3. The highest 
effect in euESC as well as in ecESC was 
observed for 5 µmol/l staurosporine, a 
generic protein kinase inhibitor, which 
was therefore chosen as the standardizing 
condition setting the maximal threshold 
for normalization of the data. ecESC 
seemed overall less prone to necrosis/
late apoptosis than euESC; however, 
high levels of cell death in both euESC 
and ecESC were also observed upon 
treatment with 10 µmol/l SGI-1776 (which 
targets PIM family protein kinases) and 
10 µmol/l ARC-775 (which targets casein 
kinase 2 [CK2]). The Akt/protein kinase 
B (PKB) inhibitor GSK690693 in the 
10 µmol/l concentration induced more 
necrosis/late apoptosis in eutopic cells; 
furthermore, the toxins bortezomib and 
MMAE were more effective in euESC 
than ecESC at all concentrations. Other 
compounds showed no effect even at the 
highest concentrations used (5–10 µmol/l).
The data for doxorubicin were not 
included as here we observed a 
characteristic fall in Sytox Blue signal 
below the value observed for the negative 
control (cells treated with 0.1% DMSO), 
which occurred in both euESC and 
ecESC from all patients. We propose that 
such behaviour is related to the mode of 
action of doxorubicin, which intercalates 
into DNA; in this way, doxorubicin 
competes with Sytox Blue for the binding 
sites, and necrosis or apoptosis assays 
based on dyes that gain fluorescence 
upon binding to DNA are incompatible 
with doxorubicin studies.
Western blotting
To gain further independent evidence 
related to the elevated efficiency of 
doxorubicin in ecESC versus euESC, 
we proceeded with an alternative assay. 
Due to the strong autofluorescence of 
doxorubicin (Wang et al., 2016), most 
of the ‘classical’ techniques such as 
imaging or fluorescence-activated cell 
sorter (FACS) using immunostaining 
or BrdU detection can be highly prone 
to artefacts; therefore, we chose 
western blotting to quantify the fall 
in procaspase-3 concentrations in 
doxorubicin-treated samples of euESC 
and ecESC from four patients (the 
same samples used for the repeated 
viability assay; see above). The ratio of 
signals corresponding to procaspase-3 
and beta-actin was quantified for each 
treatment condition, and the data were 
normalized separately for euESC and 
ecESC from each patient according to 
the corresponding negative control (0.1% 
DMSO; FIGURE 2A).
The results confirmed that 48 h of 
treatment with 10 µmol/l doxorubicin 
caused a statistically significant (P ≤ 0.05) 
difference in apoptosis in ectopic versus 
eutopic cells, with mean normalized 
procaspase-3 content reduced to 
39% (±8% SEM) in ecESC and 60% 
(±4% SEM) in euESC relative to the 
corresponding negative controls (0.1% 
DMSO) (FIGURE 2B).
mRNA sequencing
Finally, to obtain detailed insight into 
the signalling pathways affected by 
doxorubicin in euESC and ecESC, large-
scale mRNA sequencing was performed 
after 24 h incubation of cells from three 
patients with 2 µmol/l doxorubicin or 
0.1% DMSO control. The concentration 
of doxorubicin was chosen based on 
the results of the viability assay, in order 
to see a significant difference between 
euESC and ecESC while still yielding a 
sufficient population of surviving cells for 
mRNA isolation.
The comparison of treated versus 
control cells yielded 4009 significantly 
differentially expressed genes in the 
case of euESC, yet only 249 significantly 
differentially expressed genes for ecESC 
(using a base mean cut-off value of >10 
and a Padj cut-off value of <0.05). To 
shortlist genes showing a significantly 
different expression in different cells and 
treatment conditions (TABLE 4), we sorted 
the sequencing data as described in the 
section on statistical analysis, above. 
Overall, several genes that had a higher 
expression in control euESC relative to 
control ecESC (MMP1/3/10, PENK, PTN 
and GRP) or in control ecESC relative 
to control euESC (ESM1, IL33 and PTX3) 
also showed greater expression in the 
same cell type following treatment with 
doxorubicin. Furthermore, treatment 
with doxorubicin resulted in a reduced 
expression of several genes in euESC 
(e.g. DUSP1/10 and BARD1) as well as 
in ecESC (e.g. DKK1, HAS2) relative to 
the control cells of the same type. On 
the other hand, although the expression 
of some genes (such as histone cluster 
1 and 2 family members HIST1H2AE, 
HIST1H2BK and HIST2H2AA4) in 
euESC increased upon treatment with 
FIGURE 1 Viability fingerprint of euESC versus ecESC (blue and orange lines, respectively) after 22 h (A) or 22 h + 24 h (B) of treatment with 
various compounds. The compounds were chosen based on Table 3. Mean data corresponding to treatment with the highest concentrations 
of compounds was plotted. The axis scale ranges from 0% (centre of the plot) to 110% (outer line) with a grid interval of 10%. ecESC, ectopic 
endometrial stromal cell; euESC, eutopic endometrial stromal cell.
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TABLE 4 GENES SHOWING SIGNIFICANTLY DIFFERENT EXPRESSION IN CONTROL AND TOXIN-TREATED EUESC AND ECESC
Comparisona Gene names and log2FC valuesb,c
euESC control versus ecESC control Higher expression in euESC MMP12 (8.4), MMP10 (8.0), MMP3 (8.0), TFAP2C (7.4), RGCC (6.8), HTR2B 
(6.4), GRP (6.4), DIO2 (5.7), MMP1 (5.5), RBP1 (4.9), CARD16 (4.8), LEPR (4.8), 
PRDM1 (4.7), CTSK (4.6), HSPA2 (4.6), NID1 (4.6), GCNT4 (4.5), PLAU (4.5), 
PENK (4.5), PTN (4.4), IFI6 (4.2), SEMA5A (4.1), AREG (4.0), NPY1R (4.0)
Higher expression in ecESC GIPC2 (–9.7), PTX3 (–9.0), EFEMP1 (–6.1), IL33 (–6.0), SFRP4 (–4.5), PPP1R3C 
(–4.3), ESM1 (–4.0)
euESC control versus euESC + toxin Higher expression in control treatment HTR2B (8.0), CCDC107 (7.0), ING3 (6.4), BARD1 (6.2), CARNMT1 (5.9), KRT19 
(5.8), TUBA1A (5.3), DIO2 (5.2), PAN3 (5.1), DUSP1 (4.9), PKIG (4.9), PBK (4.9), 
UTP18 (4.8), CEMIP (4.7), SLC5A3 (4.5), CITED2 (4.5), CTGF(4.4), SASS6 
(4.1), DUSP10 (4.1), NOP10 (4.1)
Higher expression in toxin treatment HIST1H2AE (–7.0), INSYN2 (–6.7), TMEFF2 (–6.0), HIST1H2BPS2 (–5.2), 
HIST1H2BK (–5.0), HIST2H2AA4 (–4.8), CXCL3 (–4.7)
ecESC control versus ecESC + toxin Higher expression in control treatment HAS2 (6.9), MRPL14 (5.0), CARD16 (4.5), DKK1 (4.0)
euESC + toxin versus ecESC + toxin Higher expression in euESC GRP (7.3), MMP3 (7.1), MMP10 (6.1), PTN (5.1), RGCC (4.7), IFITM1 (4.5), SOX11 
(4.3), MMP1 (4.2), PENK (4.1)
Higher expression in ecESC ESM1 (–6.2), TFPI2 (–5.3), PTX3 (–4.9), IL33 (–4.4), BARD1 (–4.1)
a Control treatment: 24 h incubation in growth medium containing 0.1% dimethylsulphoxide; toxin treatment: 24 h incubation in growth medium containing 2 µmol/l doxorubicin.
b The binary logarithm of the fold change of averages is shown in brackets; n = 3. Negative values indicate higher expression in ectopic cells (for euESC versus ecESC comparisons) 
or in doxorubicin-treated cells (for treatment comparisons).
c Genes that are listed under more than one comparison in the table are shown in bold.
ecESC, ectopic endometrial stromal cell; euESC, eutopic endometrial stromal cell; log2FC, binary logarithm of fold change of averages.
doxorubicin relative to control cells, 
there was no significant increase in gene 
expression in toxin-treated ecESC relative 
to the control treatment.
For technical validation of the results of 
large-scale mRNA sequencing, qRT-PCR 
analysis of PTN and HSPA2 was carried 
out, as examples of genes considerably 
highly expressed in eutopic cells, 
with PTN expression elevated in both 
control and toxin-treated euESC 
relative to the correspondingly treated 
ecESC (TABLE 4). Also validated was 
the expression of PTGS2, which, 
according to large-scale mRNA 
sequencing data, possessed higher 
expression in ectopic relative to eutopic 
cells after doxorubicin treatment; 
however, the statistical significance 
of this difference was slightly higher 
than the classical cut-off Padj value of 
0.05 (Supplemental Table S4). qRT-
PCR confirmed the general trends 
observed in large-scale transcriptomic 
analysis, indicating significantly higher 
expression of PTN in both control and 
doxorubicin-treated euESC versus the 
corresponding ecESC (both P < 0.05), 
and significantly higher expression of 
HSPA2 in control euESC versus ecESC 
(P = 0.05). In addition, doxorubicin 
treatment elevated the level of PTN and 
HSPA2 in eutopic and ectopic stromal 
cells, respectively (both P < 0.05). 
Furthermore, qRT-PCR showed 
significantly higher expression of PTGS2 
in control ecESC versus euESC as well 
as doxorubicin-treated ecESC versus 
euESC (both P < 0.05), confirming 
that PTGS2 can indeed serve as an 
important target in endometriosis.
FIGURE 2 Effect of doxorubicin on procaspase-3 concentrations in euESC and ecESC. (A) Representative example of western blot membrane with 
euESC and ecESC from one patient; different lanes represent independent incubations. (B) Pooled normalized western blot data of euESC and 
ecESC from four patients (mean ± SEM). Significance of effect difference between euESC and ecESCs: *P ≤ 0.05. DMSO, dimethylsulphoxide; 
ecESC, ectopic endometrial stromal cell; euESC, eutopic endometrial stromal cell.
564 RBMO  VOLUME 39  ISSUE 4  2019
DISCUSSION
Although the molecular players 
behind the onset and progression of 
endometriosis are still unclear, several 
pathways have been closely inspected, 
with a special focus on inflammation 
processes, cell migration and adhesion, 
abnormal proliferation and resistance to 
apoptosis. The current study explored 
the differences in cell viability of euESC 
and ecESC on treatment with selective 
compounds inhibiting a focused 
number of molecular players, as well 
as compounds with a wide profile of 
biological targets. Methodologically, this 
study has two major limitations: first, 
the focus was only on stromal cells, 
yet the physiological milieu contains 
epithelial cells that may be involved 
in unique patterns of signalling and 
cellular interactions. Second, as only 
ESCs isolated from superficial peritoneal 
lesions were investigated, the observed 
results may not necessarily reflect the 
effects of toxins in other types of lesions.
Phosphorylation of proteins serves 
an example of a signalling mechanism 
that on one hand is ubiquitous, yet on 
the other can be dissected with a high 
degree of precision by selective targeting 
of the catalysing machinery – protein 
kinases. The human kinome includes 
538 protein kinases, most of which have 
been termed as potentially druggable by 
virtue of the incorporation of a narrow 
solvent-hidden pocket (ATP-binding 
site) that can be selectively targeted by 
low molecular weight inhibitors. The 
panel that was used here for screening 
included 11 inhibitors of protein kinases, 
10 of which possessed focused selectivity 
profiles, while staurosporine was selected 
as a widely used apoptosis inducer (see 
TABLE 1 and Supplemental Figure S3). 
Among the protein kinases targeted by 
the selective inhibitors were enzymes 
for which up-regulation in endometriotic 
cells has been reported: MAPKs (Ngô 
et al., 2010; Yotova et al., 2011), Akt/
PKB (Cinar et al., 2009; Shoji et al., 
2009), PIM1 (Hu et al., 2006; Jiménez-
García et al., 2017) and CK2 (Feng et al., 
2012; Llobet et al., 2008). In this study, 
inhibitors of MAPK (sorafenib), Akt/
PKB (GSK690693) and CK2 (ARC-775) 
were more effective in euESC than 
ecESC, whereas the PIM inhibitor (SGI-
1776) showed a cell type-independent 
effect: in patients whose euESC were 
affected, ecESC were also affected (see 
Supplemental Figure S1B and C). Overall, 
although the overexpression of certain 
pro-survival protein kinases in cancer 
cells can lead to the degeneration of 
other anti-apoptotic pathways and the 
establishment of the so-called oncogene 
addiction (Ruzzene and Pinna, 2010; 
Sharma and Settleman, 2007), this does 
not seem to be the case for ectopic 
endometriotic cells.
Surprisingly, CK2 inhibitor ARC-1859, 
despite featuring a structural design highly 
similar to that of ARC-775, did not reduce 
cell viability. Whereas in biochemical 
assays with recombinant CK2, the 
affinity of the unmasked counterpart of 
ARC-775 was indeed higher than that 
of the unmasked counterpart of ARC-
1859 (Rahnel et al., 2017; Viht et al., 
2015), this is hardly likely to be the only 
reason underlying the lack of potency of 
ARC-1859 in assays with ESC. Instead, it 
is likely that a more hydrophobic ATP-
site targeting a fragment of ARC-1859 
(the tetrabromobenzimidazole moiety) 
contributes to the accumulation of 
inhibitor in membranes, where it is not 
accessible by either esterases or the 
cytosolic CK2.
The effect of some compounds 
included in the panel in this study 
has previously been explored in the 
context of endometriosis. The generic 
protein kinase inhibitor staurosporine 
has been reported to demonstrate a 
greater apoptotic effect in euESC from 
patients without endometriosis than in 
ecESC from patients with endometriosis 
(Watanabe et al., 2009). In the current 
study, the sensitivity of eutopic versus 
ectopic cells to staurosporine depended 
on its concentration: whereas 5 µmol/l 
staurosporine caused greater cellular 
death in ecESC, 0.2 µmol/l staurosporine 
was more effective in euESC (TABLE 3). 
The proteasome-targeting compound 
bortezomib had been shown to reduce 
the size of endometriotic implants in 
rats (Celik et al., 2008), yet no studies 
of bortezomib in euESC from women 
with endometriosis have been reported; 
in this study study, treatment with 
bortezomib was significantly more 
efficient in euESC than in ecESC even 
after prolonged incubation (P ≤ 0.001).
The ROCK-targeting inhibitors Y-27632 
and HA-1077 have been used to 
reduce the contractility of ecESC; 
whereas Y-27632 had demonstrated no 
cytotoxicity, 0.1–10 µmol/l HA-1077 had 
caused significant apoptosis of ecESC – 
albeit after 48 h incubation (Yotova et al., 
2011; Yuge et al., 2007). In the current 
study, no reduction in viability was 
observed even after prolonged incubation 
of euESC and ecESC with either Y-27632 
or HA-1077. In principle, it is possible 
that the effect of ROCK-targeting 
inhibitors is only evident in cell motility 
assays, although it had been hoped that 
the altered dynamics of cytoskeleton 
might manifest itself as a retardation of 
proliferation. The latter was true for the 
microtubule-depolymerizing compound 
MMAE; this showed a characteristic 
concentration-independent profile of 
effect on cell viability connected to 
the mode of action of this compound, 
which serves as an antimitotic agent than 
an apoptosis inducer (Abdollahpour-
Alitappeh et al., 2017; Chen et al., 2017).
Furthermore, 22 h treatment of cells 
with some of the chosen compounds 
(including inhibitors targeting ROCK, 
Aurora family kinases or PKA) caused 
an apparent increase in viability (see 
Supplemental Table S1), which was 
alleviated after a subsequent 24 h 
incubation in medium. This abnormal 
temporary phenomenon might be 
triggered by several factors. On one 
hand, ROCK inhibitors can interfere 
with the apoptotic caspase 3-ROCK 
signalling pathway (Song and Gao, 2011), 
and consequently increase the number 
of viable cells. However, a more likely 
explanation is that, as a response to 
treatment with toxins within a certain 
time window, cell metabolism tends 
to increase, which manifests itself as 
enhanced reduction of resazurin.
Overall, the compounds that significantly 
affected the viability of cells after 22 h 
of treatment also caused a significant 
amount of cellular death according to 
the necrosis/late apoptosis assay (as 
illustrated by GSK690693, ARC-775, 
SGI-1776, staurosporine, bortezomib and 
MMAE; P ≤ 0.05). The only exception 
was CYC116, which did not trigger 
necrosis/late apoptosis yet remarkably 
reduced viability in euESC at the 
10 µmol/l concentration. It is possible 
that AURORA B-targeting CYC116 acts 
as an antimitotic substance and hence 
slows the proliferation of cells rather than 
triggering cellular death, yet it is not as 
efficient or as quick as the toxin MMAE, 
which has a similar mode of action.
Differently from other compounds used 
in the panel, doxorubicin demonstrated 
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an enhanced effect on viability in 
ectopic versus eutopic cells after 22 h 
as well as 22 h + 24 h of incubation 
at the 10 µmol/l concentration in the 
resazurin assay (FIGURE 1), and after 48 h 
of incubation in the western blot assay 
(FIGURE 2). Several mechanisms of action 
have been reported for doxorubicin. It 
accumulates in cell nuclei, intercalating 
into DNA and preventing its repair by 
topoisomerase II (Thorn et al., 2011). In 
addition, doxorubicin can be reversibly 
oxidized into an unstable semiquinone 
metabolite, which releases ROS upon 
spontaneous re-formation of doxorubicin 
(Finn et al., 2011); the liberated ROS 
attack cellular components, triggering 
cellular death. In the context of altered 
redox equilibria in ectopic versus eutopic 
endometrial cells (Kasvandik et al., 2016; 
Scutiero et al., 2017), enhanced efficiency 
of doxorubicin in ecESC might be 
explained by its redox properties.
In this way, although doxorubicin 
has been used in the treatment of 
endometrial cancer (Byron et al., 
2012; Chitcholtan et al., 2012), this 
compound might also be of remarkable 
interest for endometriosis studies. 
Unfortunately, the application of 
anthracyclines in chemotherapy has 
revealed high cardiotoxicity for this class 
of compounds, which complicates their 
use in model organisms. However, several 
pharmacokinetic and pharmacodynamic 
strategies have been actively suggested 
to prevent anthracycline-induced 
cardiotoxicity (Menna and Salvatorelli, 
2017). Furthermore, specifically in the 
context of doxorubicin, the development 
of novel derivatives with reduced side 
effects (Shaul et al., 2013) and methods 
for targeted delivery (Tran et al., 2017) 
have been intensely pursued.
The large-scale transcriptome analysis 
revealed sets of genes that featured 
significantly higher expression in eutopic 
relative to ectopic ESC or in ectopic 
relative to eutopic ESC, irrespective of the 
treatment conditions (Padj < 0.05, log2FC 
of –4 or less or ≥+4; TABLE 4). It was 
postulated that these sets might reflect 
variations in survival strategies in eutopic 
and ectopic endometrium, because it is 
likely that, after 24 h of treatment of cells 
with 2 µmol/l doxorubicin, the isolated 
mRNA profile was characteristic of the 
population of survivors.
Interestingly, the comparison of treated 
versus control cells yielded in excess of 
10 times more significantly differentially 
expressed genes in the case of euESC 
than ecESC (Padj < 0.05). Given the 
fact that the majority of candidate 
genes in the comparison of control 
versus doxorubicin-treated ecESC were 
eliminated on the basis of the Padj cut-
off, this difference originates primarily 
from the large interpatient variation of 
gene expression in the ecESC group. 
The latter can in turn be explained 
by the characteristic heterogeneity 
of lesions, especially taking into 
consideration differences in location 
of the lesions in the three patients 
whose samples were used for mRNA 
sequencing (see TABLE 2).
In euESC, among other genes, this 
set included genes encoding several 
members of the matrix metalloproteinase 
(MMP) family, and a precursor for 
the endogenous opioid peptides, 
preproenkephalin (PENK). Another gene 
with a significantly higher expression in 
both control and doxorubicin-treated 
euESC versus ecESC encodes a growth 
factor, pleiotrophin (PTN; Padj < 0.05, 
log2FC > +4); interestingly, doxorubicin 
treatment further elevated PTN 
expression in drug-treated eutopic but not 
ectopic cells. Importantly, MMP, PENK 
and PTN have previously been linked to 
endometriosis, showing significantly higher 
expression in eutopic endometrium from 
women with endometriosis relative to 
healthy controls, or lower expression in 
ectopic than eutopic tissue (Burney et al., 
2007; Chung et al., 2002; Kobayashi et 
al., 2012), thus pointing to their possible 
role in initiating peritoneal invasion. 
Furthermore, PTN has been reported to 
promote chemoresistance to doxorubicin 
in several cancers, including osteosarcoma 
and breast cancer (Huang et al., 2018; 
Wu et al., 2017). Therefore, it can be 
suggested that the lower expression 
of PTN in untreated ectopic cells is 
one of the factors responsible for the 
higher chemosensitivity of this cell type 
to doxorubicin – although it should be 
considered that the viability of euESC was 
still significantly affected by doxorubicin 
treatment (P ≤ 0.001; TABLE 3).
A similar effect on cell viability, may 
be mediated by HSPA2, which was, 
according to sequencing data, more 
highly expressed in eutopic than ectopic 
cells. Heat shock-related 70 kDa protein 
2 (HSPA2) protects cells from the 
cytotoxic and growth-inhibiting effects 
of doxorubicin by several mechanisms, 
including binding misfolded or damaged 
proteins and enabling these proteins to 
acquire proper folding, and controlling 
the duration of cell cycle arrest 
(Karlseder et al., 1996). According to 
the qRT-PCR data, the drug treatment 
enhanced the expression of HSPA2 
in ecESC (average fold change 4.5), 
suggesting a response to the toxic effect; 
however, as the initial expression of 
HSPA2 in untreated cells was much lower 
in ectopic then eutopic cells (average 
fold change –11.8), the expression was still 
less than that of the eutopic cells.
In ecESC, the set of interest defined by 
the large-scale transcriptome analysis 
and qRT-PCR data included genes 
tightly connected with immune system 
functioning: these genes encoding 
interleukin-33 (IL33), cyclooxygenase 2 
(PTGS2) and genes whose expression 
is regulated by cytokines – pentraxin 
3 (PTX3) and endothelial cell-specific 
molecule 1 (ESM1). The proteins encoded 
by all of the aforementioned genes 
have been reported to be connected 
with endometriosis (Cobellis et al., 
2004; Fagotti et al., 2004; Kobayashi 
et al., 2012; Miller et al., 2017; Pelch 
et al., 2010), showing a correlation with 
endometriosis-associated inflammation 
and angiogenesis; inhibitors of PTGS2 
have also been explored in the context 
of management of endometriosis-related 
pain (Cobellis et al., 2004). Furthermore, 
IL33 and PTGS2 have been shown to 
protect cells against doxorubicin-induced 
apoptosis, albeit in the context of tissues 
other than endometrium (Puhlmann 
et al., 2005; Singh et al., 2008; Yao et al., 
2017). The latter observation indirectly 
confirms the hypothesis that the mRNA 
profile identified for doxorubicin-
treated euESC and ecESC reflects the 
corresponding cellular survival strategies. 
The fact that the viability of ecESC 
was severely affected by doxorubicin 
treatment indicates that the major 
chemoresistance-ensuring players that 
contribute to the survival of ectopic cells 
under DNA damage and ROS-triggered 
conditions of stress might be less efficient 
than those in eutopic tissue.
The mRNA sequencing results thus 
underline the interplay of factors that 
contributing to development and 
sustainment of endometriosis, and 
necessitate the application of more 
complex models, for example enabling 
the presence of epithelial cells and/or 
involving immune system components. 
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Overall, the results of this study seem 
to have pinpointed a set of clues for 
future research into endometriosis, both 
from the aspect of showing a resistance 
of endometriotic lesions to possible 
therapeutic candidates, and in terms 
of providing candidate biomarkers and 
targets for the succeeding exploration.
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